-+ 0.00%
-+ 0.00%
-+ 0.00%

Verastem says VS-7375 posts 50% confirmed ORR in second-line KRAS G12D pancreatic cancer trial

PUBT·10/14/2026 10:01:00
Listen to the news
Verastem says VS-7375 posts 50% confirmed ORR in second-line KRAS G12D pancreatic cancer trial
  • Verastem disclosed early trial results for its oral KRAS G12D inhibitor VS-7375, showing tumor shrinkage across several advanced cancers.
  • Data were presented as an initial multi-tumor clinical update from the ongoing TARGET-D 101 Phase 1/2 study.
  • Pancreatic cancer readout showed deep, durable responses, supporting 900 mg once-daily dosing as the lead monotherapy regimen.
  • Colorectal cancer results suggested activity in heavily pretreated patients when combined with an anti-EGFR therapy.
  • FDA alignment was reached on a Phase 3 first-line metastatic pancreatic cancer trial; Verastem plans to open it by year-end 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610140600BIZWIRE_USPR_____20261014_BW862061) on October 14, 2026, and is solely responsible for the information contained therein.